Drug Development

A look back at challenge and innovation highlights in 2022 for oral solid dosage forms, this podcast episode will review industry experts’ takes on factors driving the evolution of OSD forms as well as innovations in APIs, technology, and methodology.

Tuesday, November 15th, 2022 at 10 am EDT | 8 am CDT | 7 am PD Spatial Biology is changing the drug development landscape. Validating efficacy with and actual image of the molecule interacting with the tissue provides the additional data needed to determine success or failure. Join the webinar on November 15th to learn more about the solutions Spatial Biology provides.

Advancements in soft capsule technology can enable the development of soft capsule formulations, which are becoming the preferred method of oral administration.

High-concentration injectable formulations present unique challenges.

Opportunities and developments in particle engineering are providing developers with the tools to advance drug candidates successfully.

The state of oral solid dose manufacturing is influenced by new approaches, novel technologies, and the structural evolution of the raw materials market.

Adherence to detail and thorough project management are required for successful tech transfer and scale up.

Pharma companies set goals and adopt more sustainable alternatives.

New medications show exciting outcomes for weight loss.

Experts discuss factors that can affect the outcome of an ADME study, signs that a drug compound shows promise, red flags, and key parameters to determine safety and efficacy.

FDA has accepted Ashland’s Viatel bioresorbable mPEG-PDLLA pharmaceutical excipient into the FDA Novel Excipient Review Pilot Program.

Gerresheimer has developed a new dropper insert for ophthalmic formulations that it is showcasing at CPHI 2022 in Frankfurt, Germany.

Roquette has launched excipients PEARLITOL CR-H and PEARLITOL 200 GT.

AstraZeneca’s Imjudo (tremelimumab) was approved by FDA in combination with Imfinzi (durvalumab) for treating unresectable liver cancer.

Under the new collaboration with Tempus, GSK will have access to de-identified patient data to accelerate drug discovery, improve clinical trial design, and speed up enrollment.

Aenova Group and Microcaps are partnering to enable new customized formulations for product development and life cycle management solutions.

In this episode, Ana Ladino provides expert insight into novel excipients in the current and future drug development landscape.

Patient centricity is driving change in drug discovery and development, leading to a a new dawn in therapeutics.

An early drug candidate screening strategy should incorporate clear targets to lessen late-stage failure.

How dry powder techniques can overcome limitations in biologics development and delivery to broaden routes of administration and global accessibility.

One company reaches beyond traditionally-conceived male contraceptives with Vasalgel, a reversible hydrogel injectable.

Emerging new technologies and disruptive manufacturing concepts are providing new opportunities for pharmaceutical companies.

Sponsors should explore key considerations ahead of choosing a new outsourcing partner.

An expert from Aptamer Group reveals the potential of Optimers (a type of aptamer) in the realm of drug delivery, including its targeting capabilities, scalability, and key differences between Optimers and antibody-drug conjugates.

External expertise is beneficial in helping companies select the right tools at the right stages of development to ensure success.

There are many benefits of employing a reformulation strategy, but companies must also overcome a variety of challenges too.

Numerous benefits will eventually lead to large-scale applications in pharmaceutical manufacturing.

Using an orthogonal approach to lipid nanoparticle analysis can increase the odds of project success.

Some of the greatest advancements in drug delivery are related to disposable delivery devices, vaccine adjuvants, and wearable pumps, according to Nicholas W. Warne of Pfizer.

FDA is highlighting how the Patient-Focused Drug Development program has encouraged active involvement of many patient groups in bringing their perspectives into the process of developing, testing, and approving new medicines.